List of Excipients in Branded Drug TUKYSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SEAGEN INC	TUKYSA	tucatinib	51144-001	COPOVIDONE K25-31	2030-01-19
SEAGEN INC	TUKYSA	tucatinib	51144-001	CROSPOVIDONE	2030-01-19
SEAGEN INC	TUKYSA	tucatinib	51144-001	FERRIC OXIDE YELLOW	2030-01-19
SEAGEN INC	TUKYSA	tucatinib	51144-001	MAGNESIUM STEARATE	2030-01-19
SEAGEN INC	TUKYSA	tucatinib	51144-001	MICROCRYSTALLINE CELLULOSE 102	2030-01-19
SEAGEN INC	TUKYSA	tucatinib	51144-001	POLYETHYLENE GLYCOL	2030-01-19
SEAGEN INC	TUKYSA	tucatinib	51144-001	POLYVINYL ALCOHOL	2030-01-19

TUKYSA Excipient Strategy and Commercial Opportunities for Tucatinib Tablets

Last updated: August 30, 2026

TUKYSA (tucatinib) is an immediate-release, film-coated oral tablet marketed by Pfizer following its acquisition of Seagen. Its commercial excipient opportunity is concentrated in generic development, alternate oral dosage forms, supply-chain qualification, and patient-centric reformulation rather than in the current branded tablet itself. The most practical opportunities are lactose-free or simplified tablet platforms, oral liquids for patients with swallowing difficulty, and high-containment manufacturing services for tucatinib.

What is TUKYSA and how is it formulated?

TUKYSA contains tucatinib, a selective HER2 tyrosine kinase inhibitor. The FDA-approved product is supplied as 50 mg and 150 mg film-coated tablets. The recommended adult dose is 300 mg orally twice daily, with or without food.[1]

The product is used:

• With trastuzumab and capecitabine for unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases.
• With trastuzumab for unresectable or metastatic HER2-positive colorectal cancer after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan.[1]

The tablet is an immediate-release solid oral dosage form. The FDA labeling identifies a conventional excipient system that includes:

Excipient category	Examples identified in TUKYSA labeling	Primary function
Diluent and compression aid	Lactose monohydrate, microcrystalline cellulose	Tablet mass, flow, compactibility
Disintegrant	Crospovidone	Rapid tablet breakup
Binder	Hydroxypropyl cellulose, povidone	Granule and tablet strength
Lubricant	Magnesium stearate	Ejection from tablet tooling
Glidant	Colloidal silicon dioxide	Powder flow
Surfactant	Sodium lauryl sulfate	Wetting and dissolution support
Coating materials	Hypromellose, talc, titanium dioxide, triacetin	Film formation, appearance, protection

The exact qualitative and quantitative composition, manufacturing process, and specifications remain relevant to any abbreviated new drug application or alternative formulation strategy.[1]

What excipient strategy does TUKYSA use?

TUKYSA uses a standard immediate-release tablet platform rather than a modified-release or lipid-based delivery system. The formulation strategy prioritizes manufacturability, dose flexibility, rapid disintegration, and stable oral exposure.

Dose flexibility

The 50 mg and 150 mg strengths allow a 300 mg twice-daily regimen to be administered as two 150 mg tablets per dose. The 50 mg strength also supports dose reduction when toxicity requires a lower dose. FDA labeling identifies dose reductions to 250 mg twice daily, 200 mg twice daily, and 150 mg twice daily.[1]

This creates a commercial reason to preserve multiple strengths in a generic portfolio. A single-strength product would not match the branded product's dose-adjustment utility.

Conventional tablet manufacturability

The combination of lactose, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate is compatible with common wet-granulation or direct-compression development pathways. A generic manufacturer could potentially design a materially different excipient composition while maintaining comparable dissolution and bioequivalence.

The commercial value lies in process robustness:

• Low tablet weight variation.
• Sufficient mechanical strength for coating and packaging.
• Rapid disintegration.
• Stable dissolution across the approved strength range.
• Controlled segregation of low-dose active pharmaceutical ingredient.
• Reproducible content uniformity.

Film-coating functionality

The coating improves product identification, swallowability, surface protection, and resistance to handling damage. A generic developer can usually select alternative coating polymers and colorants, subject to regulatory acceptability and pharmaceutical equivalence requirements.

Coating changes can create avoidable risks if they alter dissolution, moisture uptake, photostability, tablet hardness, or visual differentiation. A simple coating system with a well-established immediate-release profile is commercially preferable to an unnecessarily complex design.

What commercial opportunities exist for TUKYSA excipients?

The strongest opportunities are in supplying functional excipients and manufacturing services rather than creating a differentiated branded excipient product.

Lactose-free and low-allergen tablets

The current product includes lactose monohydrate. A generic or reformulated product could replace lactose with:

• Mannitol.
• Anhydrous dibasic calcium phosphate.
• Additional microcrystalline cellulose.
• Partially pregelatinized starch.
• Co-processed excipient systems.

A lactose-free version could support patients with lactose intolerance and simplify positioning in markets where lactose-free oral oncology products are preferred. The formulation must preserve tablet density, compression behavior, dissolution, and stability.

Lactose substitution is unlikely by itself to create strong intellectual-property protection. Its value is commercial and operational: broader patient acceptability, alternative supplier qualification, and reduced dependence on a specific raw-material platform.

Direct-compression platforms

Co-processed excipients could reduce manufacturing steps and improve scale-up. Relevant platforms include combinations of microcrystalline cellulose with mannitol, starch, or colloidal silica.

Potential benefits include:

• Lower granulation cost.
• Reduced solvent or water use.
• Faster scale-up.
• More consistent flow.
• Improved tablet weight control.
• Reduced equipment requirements.

The principal development risk is content uniformity. Tucatinib is administered at a relatively high daily dose, but the 50 mg strength still requires precise control of active distribution and tablet-to-tablet variability.

High-containment contract manufacturing

Tucatinib is a potent small-molecule oncology drug. The commercial manufacturing opportunity includes contained dispensing, granulation, compression, coating, and packaging.

Service providers can differentiate through:

• Closed charging and discharging systems.
• Isolator-based powder handling.
• Occupational exposure monitoring.
• Dedicated cleaning validation.
• High-potency active pharmaceutical ingredient handling.
• Cross-contamination control.
• Segregated packaging operations.

For generic manufacturers, containment capability may be a larger barrier than the excipient system itself.

Supply-chain dual sourcing

The formulation uses widely available excipients, which limits exclusivity but creates opportunities for qualified second sources. Priority materials include:

• Lactose monohydrate.
• Microcrystalline cellulose.
• Crospovidone.
• Povidone.
• Hydroxypropyl cellulose.
• Film-coating polymers.
• Magnesium stearate.

Suppliers with compendial grades, consistent particle-size distributions, low bioburden, and strong regulatory documentation have an advantage. Excipient changes can affect dissolution and process performance even when the chemical identity remains unchanged.

What alternative formulations could compete with TUKYSA tablets?

Alternative formulations could address adherence, swallowing difficulty, dose flexibility, or administration in patients receiving intensive combination therapy.

Oral suspension

An oral suspension could serve patients who cannot swallow tablets. The main technical problems are tucatinib's aqueous solubility, physical stability, taste, preservative strategy, dose uniformity, and container compatibility.

A suspension would require evidence on:

• Chemical stability after reconstitution.
• Sedimentation and redispersibility.
• Shake-time requirements.
• Dosing-device accuracy.
• Microbial control.
• In-use stability.
• Sorption to bottles or syringes.
• Taste masking.

An oral liquid may be commercially useful in pediatric investigations or adult oncology patients with dysphagia. The commercial case is stronger if it can support dose titration without requiring multiple tablet strengths.

Orally disintegrating tablet

An orally disintegrating tablet could improve administration for patients with swallowing difficulty. It would require taste masking and control of friability, moisture sensitivity, and mouthfeel.

The key commercial limitation is that patients may still need a relatively large amount of drug per dose. An ODT must deliver 300 mg twice daily or provide a practical multi-unit dosing approach.

Sprinkle or multiparticulate formulation

A sprinkle formulation could allow administration with soft food. Multiparticulates may provide improved dose flexibility and swallowing performance, but they add manufacturing complexity and require careful control of content uniformity and release after mixing with food.

Fixed-dose combination products

TUKYSA is commonly used with capecitabine and trastuzumab, but a fixed-dose oral combination with capecitabine is unlikely to be straightforward. The drugs have different dose schedules, toxicity management requirements, pharmacokinetic characteristics, and dose-adjustment rules.

A co-pack or adherence kit is more commercially practical than a single fixed-dose tablet. Packaging could combine tucatinib and capecitabine schedules while preserving independent dose modification.

What patents protect TUKYSA and its excipient strategy?

Tucatinib's core commercial protection is expected to center on the active ingredient, pharmaceutical compositions, methods of treating HER2-positive cancers, and manufacturing or solid-state subject matter. Excipients generally have limited standalone protection unless they are part of a specifically claimed composition or process.

A generic developer should separate the freedom-to-operate analysis into four claim groups:

Claim group	Relevance to a TUKYSA competitor
Tucatinib compound claims	Core active-ingredient risk
Pharmaceutical composition claims	Potential risk from specified excipient combinations or ratios
Method-of-use claims	Risk for HER2-positive breast and colorectal cancer indications
Manufacturing and solid-state claims	Risk from particular processes, polymorphs, salts, or intermediates

The FDA Orange Book should be reviewed for current listed patents associated with NDA 213839. Orange Book listings and patent expirations can change through patent-list updates, pediatric extensions, terminal disclaimers, or regulatory actions.[2]

An excipient substitution strategy can reduce exposure to composition claims, but it does not eliminate compound or method-of-use risks. A non-infringing formulation still requires a valid regulatory pathway and may face Paragraph IV litigation if the applicant challenges listed patents.

When does TUKYSA lose exclusivity?

TUKYSA's regulatory exclusivity began with the FDA's approval of NDA 213839 in April 2020. The initial approval included orphan-drug exclusivity for the applicable breast-cancer indication, while the colorectal indication received a later supplemental approval.[1]

Regulatory exclusivity and patent exclusivity must be assessed separately:

• New chemical entity exclusivity generally runs for five years from the first approval of the active ingredient.
• Orphan-drug exclusivity may apply to a specific disease or indication for seven years.
• Patent term depends on issued claims, patent-term adjustment, patent-term extension, and terminal disclaimers.
• Method-of-use patents may remain relevant after composition patents expire.
• A generic applicant can file a Paragraph IV certification before patent expiration and litigate the asserted patents.

The commercial launch date for a generic depends on the earliest enforceable patent barrier, settlement terms, 180-day exclusivity issues, regulatory approval, and the applicant's litigation posture. A patent expiration date should not be treated as an automatic launch date.

What FDA regulatory issues affect a tucatinib excipient strategy?

For a conventional generic tablet, the principal regulatory targets are pharmaceutical equivalence, bioequivalence, dissolution, impurity control, stability, and manufacturing comparability.

Excipient changes can trigger questions involving:

• Inactive Ingredient Database precedent.
• Maximum daily exposure.
• Nitrosamine or elemental-impurity risk.
• Residual solvents.
• Microbial quality.
• Extractables and leachables.
• Food-effect behavior.
• Dissolution across pH conditions.
• Tablet identification and scoring.
• Compatibility with high-potency manufacturing.

A 505(b)(2) pathway may be more suitable for an oral liquid, ODT, or other materially changed dosage form. The applicant would need to establish a bridge to the listed drug and address formulation-specific clinical or pharmacokinetic requirements.[3]

How strong is the commercial patent estate for TUKYSA?

The estate is commercially stronger when claims cover the tucatinib molecule, approved combinations, and clinically important HER2-positive indications. Excipient-only differentiation is comparatively weak because many conventional excipients can be substituted without changing the therapeutic product.

The most important risk variables are:

1. The current Orange Book-listed patents.
2. The expiration and enforceability of compound and composition claims.
3. The scope of method-of-use claims.
4. Any settlement between Pfizer, Seagen-related entities, and generic applicants.
5. The availability of non-infringing formulations.
6. The timing of ANDA approvals and first-filer rights.

A generic developer should prioritize a claim chart comparing the proposed tablet's active ingredient, composition, manufacturing process, and labeling. Excipient selection should be integrated into that analysis from the beginning, not treated as a late-stage formulation decision.

What generic launch scenarios exist for TUKYSA?

Three launch scenarios are commercially plausible.

At-risk launch

A generic company launches before all asserted patents expire after obtaining approval and accepting litigation risk. This strategy can generate early market share but exposes the company to damages and an injunction if the patent holder prevails.

Authorized or settlement-based entry

A patent settlement may permit entry before the last patent expiration date. The economic value depends on the negotiated launch date, supply rights, manufacturing restrictions, and whether multiple generic companies receive entry rights.

Post-expiration competition

Several manufacturers enter after the enforceable patent estate ends. Price erosion would likely be rapid, although oncology products with complex supply requirements and limited manufacturers may retain higher margins than high-volume primary-care generics.

How does TUKYSA compare with other HER2-directed oral products?

Tucatinib differs from antibody therapies such as trastuzumab and pertuzumab because it is an oral small molecule with tablet-based manufacturing and no biosimilar pathway. Biosimilar risk applies to the combination partners, not to tucatinib itself.

Product type	Example	Primary competition risk
Oral HER2 kinase inhibitor	Tucatinib/TUKYSA	Small-molecule generic entry
Monoclonal antibody	Trastuzumab	Biosimilar competition
Antibody-drug conjugate	Trastuzumab deruxtecan	Biologic and formulation complexity
Oral chemotherapy partner	Capecitabine	Established generic competition

This distinction supports a co-packaging and adherence opportunity. As capecitabine and trastuzumab face competitive pressure, tucatinib may become the higher-value protected component of the treatment regimen.

Key Takeaways

• TUKYSA is an immediate-release tucatinib tablet available in 50 mg and 150 mg strengths.
• Its excipient system is conventional and potentially reproducible with alternative materials.
• The strongest excipient opportunities are lactose-free tablets, direct-compression platforms, high-containment manufacturing, and qualified second-source supply.
• Oral suspensions, ODTs, and sprinkle formulations could address swallowing and dose-flexibility needs but require substantial stability and bioavailability work.
• Excipient substitution may reduce composition-claim risk but does not remove compound, method-of-use, or manufacturing patent risks.
• TUKYSA has no biosimilar pathway because tucatinib is a small molecule; competition will arise through generic drug applications.
• The Orange Book and current patent records for NDA 213839 control the timing analysis for Paragraph IV challenges and generic entry.
• Co-packs and adherence systems with capecitabine are more commercially practical than a fixed-dose tucatinib-capecitabine tablet.

FAQs

Can lactose be removed from a generic TUKYSA tablet?

Yes. Lactose can potentially be replaced with mannitol, microcrystalline cellulose, starch-based materials, or co-processed excipients, provided the product meets dissolution, stability, content-uniformity, and bioequivalence requirements.

Is an oral liquid version of tucatinib commercially attractive?

It could be attractive for patients with dysphagia or future pediatric use. Its value depends on solving solubility, taste, chemical stability, preservative, dosing-device, and in-use stability problems.

Does changing the excipient composition avoid TUKYSA patent infringement?

No. A different excipient system may avoid a narrow composition claim, but it does not necessarily avoid patents covering tucatinib, therapeutic methods, salts, polymorphs, intermediates, or manufacturing processes.

Are tucatinib biosimilars possible?

No. Tucatinib is a chemically synthesized small molecule. Competitors would generally pursue generic-drug pathways rather than biosimilar applications.

What is the best commercial role for excipient suppliers in TUKYSA competition?

The strongest role is supplying high-functionality, compendial excipients with consistent particle size and process performance, supported by dual-source qualification, regulatory documentation, and high-potency contract manufacturing capability.

References

1. U.S. Food and Drug Administration. (2023). TUKYSA (tucatinib) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2022). Changes to an approved NDA or ANDA: Questions and answers.